K102495 P1/2

Philips Medical Systems

PHILIPS

Patient Monitoring
Quality & Regulatory Group
3000 Minuteman Road
Mailstop 0480
Andover, MA 01810
Tel: (978) 659-3000
Fax: (978) 685-5624

SEP 30 2010

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 CFR §807.92.

The submitter of this premarket notification is:

Theresa Poole
Regulatory Affairs Specialist
Patient Monitoring
Philips Medical Systems
3000 Minuteman Road, MS0480
Andover, MA 01810-1099

Tel: 978 659 7621
Fax: 978 685 5624
Email: theresa.poole@philips.com

This summary was prepared on 30 August 2010.

The name of this device is the IntelliVue Information Center
Classification names are as follows:

Classification	ProCode	Description
None	74 MHX	Physiological Monitor, Patient Monitor
870.1025, II	74 DSI	Arrhythmia Detector and Alarm
870.1025, II	74 MLD	Monitor, ST Alarm
870.2800, II	74 DSH	Recorder, Magnetic Tape, Medical
870.2300, II	74 MSX	System, Network and Communication, Physiological Monitors

The M3290B IntelliVue Information Center (IIC) is substantially equivalent to the previously cleared M3290A IntelliVue Information Center Software, Release L.0 marketed pursuant to K081983, K062271, K050742, K041741, K040955, K040357, K031403, K023698, K021422, K011093, K001057, K000854, K993907, K993171, and K964832.

The IntelliVue Information Center Software is central station software that runs on off-the-shelf Windows PCs and servers which can connect to recorders for waveform printing. It displays physiologic waves and parameters from multiple patient connected monitors and telemetry

devices in summary or detailed format, and generates alarm signals. It provides retrospective review applications and a variety of data import and export functions.

The device has the same Indications for Use and Intended Use Statement as the legally marketed predicate devices.

The device has the same technological characteristics as the legally marketed predicate devices.

Verification, validation, and testing activities, where required to establish the performance, functionality, and reliability characteristics of the new device with respect to the predicate are performed. Testing involved system level tests, performance tests, and safety testing from hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate device and test results showed substantial equivalence. The M3290B IntelliVue Information Center Software meets all defined reliability requirements and performance claims.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room –WO66-G609
Silver Spring, MD 20993-0002

Ms. Theresa Poole
Regulatory Affairs Specialist
Philips Medical Systems
3000 Minuteman Road, MS 0480
Andover, Massachusetts 01810-1099

SEP 30 2010

Re: K102495
Device Name: M3290B IntelliVue Information Center Software release A.0
Regulation Number: 21 CFR 870.1025
Regulation Name: Patient physiological monitor (with arrhythmia detection or alarms)
Regulatory Class: Class II (Two)
Product Codes: MHX, DSI, MLD, DSH, MSX
Dated: August 30, 2010
Received: August 31, 2010

Dear Ms. Poole:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

for Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

3.1 **ODE Indications Statement**

K102495

Indications for Use

510(k) Number (if known): K102495

SEP 30 2010

Device Name: M3290B IntelliVue Information Center Software Release A.0

Indications for Use:

Indicated for central monitoring of multiple adult, pediatric, and neonatal patients; and where the clinician decides to monitor cardiac arrhythmia of adult, pediatric, and neonatal patients and/or ST segment of adult patients to gain information for treatment, to monitor adequacy of treatment, or to exclude causes of symptoms.

Prescription Use Yes (Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use No (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular Devices

510(k) Number K102495